Divi's Laboratories Limited

NSEI:DIVISLAB Stock Report

Market Cap: ₹1.6t

Divi's Laboratories Valuation

Is DIVISLAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DIVISLAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: DIVISLAB (₹5977.1) is trading above our estimate of fair value (₹1280.96)

Significantly Below Fair Value: DIVISLAB is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DIVISLAB?

Key metric: As DIVISLAB is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for DIVISLAB. This is calculated by dividing DIVISLAB's market cap by their current earnings.
What is DIVISLAB's PE Ratio?
PE Ratio86.4x
Earnings₹18.36b
Market Cap₹1.57t

Price to Earnings Ratio vs Peers

How does DIVISLAB's PE Ratio compare to its peers?

The above table shows the PE ratio for DIVISLAB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average48.3x
SYNGENE Syngene International
70.5x19.3%₹341.4b
INDGN Indegene
41.1x18.4%₹152.0b
AKUMS Akums Drugs and Pharmaceuticals
34.5xn/a₹91.4b
INNOVACAP Innova Captab
46.8x29.7%₹53.3b
DIVISLAB Divi's Laboratories
86.4x23.7%₹1.6t

Price-To-Earnings vs Peers: DIVISLAB is expensive based on its Price-To-Earnings Ratio (86.4x) compared to the peer average (48.3x).

Price to Earnings Ratio vs Industry

How does DIVISLAB's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
DIVISLAB 86.4xIndustry Avg. 30.7xNo. of Companies7PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: DIVISLAB is expensive based on its Price-To-Earnings Ratio (86.4x) compared to the Asian Life Sciences industry average (30.7x).

Price to Earnings Ratio vs Fair Ratio

What is DIVISLAB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DIVISLAB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio86.4x
Fair PE Ratio54.6x

Price-To-Earnings vs Fair Ratio: DIVISLAB is expensive based on its Price-To-Earnings Ratio (86.4x) compared to the estimated Fair Price-To-Earnings Ratio (54.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DIVISLAB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹5,977.10
₹5,512.44
-7.8%
18.6%₹6,983.00₹3,590.00n/a27
Nov ’25₹5,903.55
₹4,627.31
-21.6%
20.1%₹6,850.00₹3,000.00n/a26
Oct ’25₹5,423.80
₹4,457.08
-17.8%
17.0%₹5,740.00₹3,000.00n/a26
Sep ’25₹5,093.90
₹4,457.08
-12.5%
17.0%₹5,740.00₹3,000.00n/a26
Aug ’25₹4,917.90
₹3,922.42
-20.2%
14.9%₹4,767.00₹2,644.00n/a26
Jul ’25₹4,602.10
₹3,879.88
-15.7%
14.5%₹4,767.00₹2,643.00n/a26
Jun ’25₹4,307.20
₹3,871.33
-10.1%
14.5%₹4,767.00₹2,643.00n/a27
May ’25₹4,002.40
₹3,442.36
-14.0%
13.8%₹4,372.00₹2,541.00n/a25
Apr ’25₹3,567.95
₹3,414.52
-4.3%
13.5%₹4,372.00₹2,541.00n/a23
Mar ’25₹3,482.40
₹3,399.92
-2.4%
13.4%₹4,372.00₹2,541.00n/a24
Feb ’25₹3,655.40
₹3,345.63
-8.5%
14.3%₹4,147.00₹2,344.00n/a24
Jan ’25₹3,915.90
₹3,289.25
-16.0%
14.3%₹4,069.00₹2,344.00n/a24
Dec ’24₹3,792.70
₹3,300.68
-13.0%
14.0%₹4,069.00₹2,344.00n/a25
Nov ’24₹3,346.05
₹3,361.00
+0.4%
14.2%₹4,300.00₹2,615.00₹5,903.5524
Oct ’24₹3,765.15
₹3,354.38
-10.9%
14.6%₹4,300.00₹2,615.00₹5,423.8024
Sep ’24₹3,589.30
₹3,354.38
-6.5%
14.6%₹4,300.00₹2,615.00₹5,093.9024
Aug ’24₹3,639.50
₹3,097.87
-14.9%
11.5%₹3,610.00₹2,585.00₹4,917.9023
Jul ’24₹3,583.60
₹3,061.41
-14.6%
11.6%₹3,610.00₹2,585.00₹4,602.1022
Jun ’24₹3,525.40
₹3,046.39
-13.6%
12.0%₹3,610.00₹2,450.00₹4,307.2023
May ’24₹3,267.90
₹2,946.30
-9.8%
11.7%₹3,850.00₹2,380.00₹4,002.4023
Apr ’24₹2,823.35
₹2,962.61
+4.9%
13.6%₹3,890.00₹2,380.00₹3,567.9523
Mar ’24₹2,845.30
₹3,024.58
+6.3%
16.3%₹4,450.00₹2,380.00₹3,482.4024
Feb ’24₹3,356.85
₹3,552.96
+5.8%
13.1%₹4,450.00₹2,829.00₹3,655.4024
Jan ’24₹3,413.20
₹3,560.33
+4.3%
12.9%₹4,450.00₹2,829.00₹3,915.9024
Dec ’23₹3,409.05
₹3,560.33
+4.4%
12.9%₹4,450.00₹2,829.00₹3,792.7024
Nov ’23₹3,836.45
₹4,013.09
+4.6%
12.3%₹5,100.00₹2,887.00₹3,346.0523

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Caplin Point Laboratories

₹148.3b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,952.15

7D

-0.09%

1Y

60.0%

Bal Pharma

₹2.1b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹130.88

7D

14.0%

1Y

21.4%

Vilin Bio Med

₹313.9m

Engages in the manufacture and sale of pharmaceutical products in India.

VILINBIO

₹22.50

7D

-4.9%

1Y

6.1%